Clinical Trials Directory

Trials / Completed

CompletedNCT01305252

A 48-week Study of the Effect of Dual Therapy (Inhaled Treprostinil and Tadafafil) Versus Monotherapy (Tadalafil).

CombinatiON Up-FRON t Therapy for PAH - A Phase 4, Randomized, Multicenter Study of Inhaled Treprostinil in Treatment naïve Pulmonary Arterial Hypertension Patients Starting on Tadalafil

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
21 (actual)
Sponsor
Stanford University · Academic / Other
Sex
All
Age
18 Years – 69 Years
Healthy volunteers
Not accepted

Summary

The Study Hypothesis: Aggressive, upfront, dual therapy for treatment-naïve NYHA I/II/III PAH is superior to a traditional "step-up" approach. The study will evaluate: 1. Impact of dual, upfront, therapy on cardiovascular parameters in PAH as gauged by cardiac magnetic resonance imaging (cMRI) at 24 weeks and event free survival at outcome at 48 weeks. 2. Value of novel biomarkers (NT-pro BNP, Mts1/S100A4, and insulin resistance) and cutting-edge imaging technologies (cardiac MRI) as newer endpoints for clinical trials in PAH. 3. Utility of longer clinical trial design with the use of combined clinical events as time to clinical worsening surrogate

Detailed description

This is a 48 week interventional study evaluating the effect of Dual therapy ( Treprostinil inhalations and Tadalafil) versus Mono therapy (Tadalafil). The impact of the therapy on cardiovascular parameters in PAH measured at 24 weeks and event free survival outcome at 48 weeks.

Conditions

Interventions

TypeNameDescription
DRUGtreprostinil inhalationsTreprostinil inhalation QID starting at 3 breaths per inhalation \& gradually increasing to 9 breaths. Each breath provides approximately 6mcg of treprostinil.
DRUGtadalafiltadalafil 20mg QD PO increasing to 40mg QD as tolerated

Timeline

Start date
2010-07-01
Primary completion
2014-09-01
Completion
2014-09-01
First posted
2011-02-28
Last updated
2017-06-02
Results posted
2017-06-02

Locations

2 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT01305252. Inclusion in this directory is not an endorsement.